Immunotherapy has transformed cancer treatment by harnessing the body's own immune system to fight disease. But many engineered immune cells lose strength quickly after they enter the body, especially ...

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...

Scientists have uncovered new genetic rules that determine whether the immune system’s “killer” T cells remain powerful long-term defenders or become worn out and ineffective. By building a detailed ...

A multi-institutional study led by researchers at UNC Lineberger Comprehensive Cancer Center, the Salk Institute for Biological Studies, and UC San Diego has uncovered new genetic rules that determine ...

Selected as a C-Further program with up to $1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial ...

MiNK Therapeutics collaborates with C-Further to advance PRAME-targeted iNKT cell therapy for paediatric cancer: New York Thursday, March 12, 2026, 10:00 Hrs [IST] MiNK Therapeuti ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today ...

A Markov model was constructed to compare CMT versus RT alone for patients with early-stage ENKTCL, according to five risk groups defined by NRI model. Transition probabilities, effectiveness, and ...

Active aldehydes drive T cell exhaustion in the tumor microenvironment This motivated a team of researchers from Kyoto University to investigate this conundrum. A key physiological role of FAO is the ...